In this case, the treatment regimen of anlotinib combined with EP in the transformation of SCLC after resistance to first-generation EGFR TKIs therapy made the patient have a good clinical outcome with PFS of 10.1 months, and the OS more than 36 months. The gene discussed is EGFR; the disease is small cell lung carcinoma.